REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time Jefferies Global Healthcare Conference in London, England on Tuesday, November 18,... Read More

CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced an upcoming poster presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 5-9, 2025, in National Harbor,... Read More

REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight Time H.C. Wainwright 27 th Annual Global Investment Conference in New... Read More

LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 Data readouts for CHS-114 and casdozokitug on track for 1H 2026 Q2 2025 ending cash, cash equivalents and marketable securities of $238 million Conference call today at 5:00 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter ended June 30,... Read More

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general... Read More

REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination... Read More

First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a... Read More

Strategic transformation to innovative oncology completed in Q2 2025 – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout... Read More

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will... Read More

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming conferences: Citizens Life Science Conference in New York, NY on Thursday, May 8, 2025 at 9:00 a.m. Eastern Daylight Time / 6:00 a.m. Pacific Daylight Time – Webcast Link HCW BioConnect @ Nasdaq NYC 2025 in New York, NY on Tuesday, May... Read More

CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026 Coherus to host investor and analyst call... Read More

$250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts Coherus to focus exclusively on its innovative novel oncology programs including: LOQTORZI ® , a revenue-generating and differentiated PD-1 inhibitor; Casdozokitug, a first-in-class interleukin-27 (IL-27) antagonist; CHS-114, a highly selective CCR8 (chemokine receptor 8) antibody REDWOOD... Read More

Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company,” NASDAQ: CHRS) announced today that it has entered into privately negotiated transactions (the “Repurchases”) with certain holders (the “Holders”) of its 1.500% Convertible Senior Subordinated Notes due... Read More

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck... Read More

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures UDENYCA ® net revenue increased 62% year-over-year LOQTORZI ® net revenue increased 29% quarter-over-quarter UDENYCA divestiture on track with Special Meeting of Shareholders taking place March 11, 2025; transaction expected to close late in the first quarter or early in the second quarter of 2025 Post divestiture expected cash of... Read More

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.... Read More

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus’... Read More

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate Antitumor activity was observed across both viral and non-viral etiologies Data support continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC Randomized Phase 2 trial evaluating casdozokitug/bevacizumab/toripalimab now open... Read More

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc . (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website:... Read More

Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent... Read More

Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody Post-closing proceeds... Read More

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET. The panel discussion will be accessible via webcast through a link on the... Read More

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast... Read More

Net revenue of $65.0 million in Q2 2024 CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI Bryan McMichael Appointed as Chief Financial Officer Conference call today at 5:00 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended June... Read More

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast... Read More

REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc . (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million. The closing of the transaction occurred on June 26, 2024. Meitheal Pharmaceuticals, Inc. (Meitheal), a wholly owned subsidiary of HKF, will continue to... Read More

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting... Read More

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the... Read More

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the... Read More

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the... Read More

Net revenue of $77.1 million in Q1 2024 CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 Conference call today at 5:00 p.m. Eastern Time REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended... Read More

New $38.7 million term loan with a May 2029 maturity $37.5 million royalty monetization financing based on future sales of LOQTORZI ® and UDENYCA ® REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining $75 million... Read More

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule... Read More

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will... Read More

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664 Title: Preliminary Results of a Phase 1,... Read More

In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion Mechanism may enhance antitumor responses with immunotherapy First novel immuno-oncology product candidate discovered and developed by Coherus The CHS-1000 IND submission is planned for Q2 2024 REDWOOD CITY, Calif., April 08, 2024... Read More

Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 CIMERLI ® net sales of $52.4 million in the fourth quarter and $125.4 million in FY 2023 LOQTORZI™ and UDENYCA ONBODY™ successfully launched in Q1 2024 Reduction of work force of 30% for 2024 initiated on March 7, 2024 Conference call today at 5:00 p.m.... Read More

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A... Read More

Upfront cash payment of $170 million strengthens capital structure – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to... Read More

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading... Read More

Innovative design enables five-minute pegfilgrastim-cbqv delivery time – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDENYCA ® – REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) presentation of UDENYCA ®... Read More

Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 Revenue covenant reduced to $125 million Term loan annual interest expense projected to be reduced by ~70% REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it has entered into an agreement with Pharmakon Advisors, LP to revise the terms of its loan agreement... Read More

Transaction aligns to Coherus’ strategic focus on oncology Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it has entered into an agreement to divest its CIMERLI ® (ranibizumab-eqrn) ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz... Read More

Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that may be associated with IL-27 pathway biomarkers Data support continued evaluation of casdozo with VEGF and PD-(L)1 blockade in HCC, including further clinical development to... Read More

REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus... Read More

Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy Indicated in combination with chemotherapy for 1 st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status LOQTORZI is now available for... Read More

Innovative design enables five-minute pegfilgrastim delivery time Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgrastim REDWOOD CITY, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative... Read More

REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the common stock of the Company to five newly hired employees with a per share exercise price of $1.94, the closing trading... Read More

NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI monotherapy also recommended as the only preferred regimen in subsequent lines of therapy LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy REDWOOD CITY,... Read More

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the company to pursue other opportunities. Mr. Stilwell’s last day of employment with Coherus will be December 31, 2023, with ongoing service provided beyond that date by mutual agreement. Coherus will appoint a new interim Principal... Read More

Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses Data support continued evaluation of casdozokitug in combination with anti-PD-1 antibody treatments including ongoing Phase 2 cohort of casdozokitug with toripalimab in treatment refractory NSCLC REDWOOD CITY, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) --... Read More

Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status Treatment resulted in a 37% reduction in the risk of death versus chemotherapy alone LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy and will be... Read More

Net revenue rose 27% from prior quarter to $74.6 million CIMERLI ® net sales increased 50% to $40 million compared to prior quarter LOQTORZI™ now approved with launch planned for the first quarter of 2024 Conference call today at 5:00 p.m. Eastern Time REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30,... Read More

Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug Anti-CCR8 antibody, CHS-114, depletes tumor-infiltrating Treg cells and activates NK cells in dissociated head and neck squamous cell carcinoma (HNSCC) tumors Anti-PD-1 antibody, LOQTORZI™ (toripalimab-tpzi), exhibits potent T cell... Read More

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Truist Securities BioPharma Symposium In New York City on Wednesday, November 8, 2023, for 1x1 meetings only. UBS Biopharma Conference in Miami on Thursday, November 9, 2023, a fireside chat presentation at 11:30 a.m. Eastern... Read More

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference... Read More

LOQTORZI is the first and only FDA-approved treatment for NPC Indicated in combination with chemotherapy for 1 st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status Conference today at 4:30 p.m. Eastern Daylight Time REDWOOD CITY,... Read More

REDWOOD CITY, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,500 shares of the common stock of the Company to eight newly hired employees with a per share exercise price of $3.54, the closing trading... Read More

Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemotherapy Toripalimab demonstrated twelve-fold higher binding affinity to PD-1 compared to pembrolizumab In vitro studies show significantly higher activation of T cells compared to pembrolizumab in multiple assay systems REDWOOD... Read More

Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler REDWOOD CITY, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the Company has resubmitted the Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™, the company's on-body injector presentation of UDENYCA® (pegfilgrastim-cbqv), to the... Read More

CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* Demonstrated safety and efficacy in clinical trials and real-world settings Robust and reliable supply addresses market need and expands anti-VEGF options across the retinal market REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that sales of CIMERLI® (ranibizumab-eqrn) to... Read More

Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments Many rare cancers, such as nasopharyngeal carcinoma (NPC), represent an area of high unmet need and currently have no treatment options approved in the U.S. REDWOOD CITY, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.... Read More

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA. Abstract #1351: Identifying IL-27 dependent biomarkers in lymphocytes, NK cells, and myeloid cells... Read More

No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL No additional UDENYCA® ONBODY™ clinical data or trials have been requested by the FDA Toripalimab inspections completed REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, NASDAQ: CHRS), a commercial-stage... Read More

REDWOOD CITY, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective September 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 109,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $4.51, the closing trading... Read More

Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment I-O combinations will potentially expand toripalimab opportunity into large indications with high unmet need REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously... Read More

REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Citi's 2023 18th Annual BioPharma Conference in Boston on Wednesday, September 6, 2023, including participation in an I-O Panel Discussion at 3:30 p.m. EDT. 2023 Wells Fargo Healthcare Conference in Boston on Thursday,... Read More

REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 77,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $4.47, the closing trading price on... Read More

Net revenue rose 81% from prior quarter to $58.7 million CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter UDENYCA® autoinjector launched in late May, and YUSIMRY™ launched in July Planned merger with Surface Oncology expected to significantly advance next-generation immuno-oncology pipeline Conference call today at 5:00 p.m. Eastern Daylight Time REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) --... Read More

REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call... Read More

REDWOOD CITY, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 187,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $4.17, the closing trading price on the... Read More

Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple product launches REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of... Read More

First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of more than 85% compared to Humira Innovative distribution plan provides employers a low-cost, high-quality treatment option from Coherus and the highest quality of patient... Read More

$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® YUSIMRY™ meets high unmet need by providing patients, employers, physicians and payers with low-cost access to adalimumab treatment REDWOOD CITY, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.... Read More

REDWOOD CITY, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 48,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $3.84, the closing trading price on... Read More

Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients No treatments are approved for NPC in the US; if approved, toripalimab will address a critical unmet need REDWOOD CITY, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Coherus... Read More

YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and shipping fees DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Mark Cuban Cost Plus Drug Company, PBC (“Cost Plus Drugs” or “Mark Cuban Cost Plus Drug Company”) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq:... Read More

REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors), the lowest price announced to date of any adalimumab offering in the United States. With Humira® currently priced at $6,922 per carton of two autoinjectors,... Read More

UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home UDENYCA® AI fulfills high unmet need by giving providers a new, innovative option that offers patients greater choice, independence and flexibility REDWOOD CITY, Calif.,... Read More

REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase... Read More

REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less the underwriting... Read More

UDENYCA ® autoinjector approved and ready for May 2023 launch CIMERLI ® product-specific Q-code now facilitating electronic reimbursement following April 1 activation FDA inspection of toripalimab manufacturing site scheduled for May 2023 Toripalimab launch anticipated in Q3 2023, if approved YUSIMRY™ ready for planned July 2023 launch FDA review of UDENYCA ® OBI BLA supplement progressing; launch anticipated in 2023, if... Read More

REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Bank of America Merrill Lynch Global Healthcare 2023 Conference in Las Vegas on Thursday, May 11, 2023; fireside chat at 10:15 a.m. PDT UBS Global Healthcare Conference at UBS NY headquarters on Tuesday, May 23, 2023 for 1x1... Read More

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023. Starting at 5:00 pm ET on May 8, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be... Read More

SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that data presentations of four toripalimab pivotal clinical studies will be presented at the upcoming ASCO Annual Meeting, which is being held from June 2-6, 2023 at McCormick Place in Chicago.... Read More

Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 FDA is planning the toripalimab manufacturing site inspection in Q2 2023 UDENYCA ® autoinjector approved by FDA; UDENYCA ® on-body injector under review by FDA Planning underway for potential 2023 commercial launches of toripalimab, YUSIMRY™, UDENYCA ® AI and UDENYCA ® OBI Conference call today at 5 p.m. ET REDWOOD CITY, Calif., March... Read More

UDENYCA ® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy An additional presentation, the UDENYCA ® proprietary on-body injector (OBI) device, is under review by the FDA with anticipated approval this year REDWOOD CITY, Calif., March 06, 2023 (GLOBE... Read More

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43rd Annual Cowen Health Care Conference on Tuesday, March 7 th at 2:10 p.m. ET Barclays 2023 Global Healthcare Conference on Tuesday, March 14 th at 4:05 p.m. ET Audio webcasts of these presentations will be available... Read More

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A... Read More

SHANGHAI, China and REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study JUPITER-02 ( NCT03581786 ), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating... Read More

Q-Code assigned to CIMERLI ® for Medicare claims processing effective for dates of service on and after April 1, 2023 COHERUS Solutions™ patient services hub is available to facilitate successful access and reimbursement REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new code... Read More

REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 1, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $8.65, the closing trading... Read More

REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH (Klinge Biopharma) for the exclusive commercialization rights to FYB203, a biosimilar candidate to Eylea® (aflibercept), in the United States. The parties expect to complete the transaction in Q1 2023, and Coherus... Read More

REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus... Read More

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in the U.S. as quickly as possible - SHANGHAI, China and REDWOOD CITY, Calif., Dec. 25, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi... Read More

FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA Coherus and Junshi Biosciences are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in the U.S. as quickly as possible - SHANGHAI, China, and REDWOOD CITY, Calif., Dec. 24, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi... Read More